Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVENUE: Esketamine for MDD with Acute Suicidal Ideation in Adolescents
NCT07227454Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Apr 2031
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of esketamine in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Jan 2026; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07227454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227454.